Q-omics provides the consensus-scored DNASE2B profile across patient tissues and cancer cell-line models. DNASE2B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DNASE2B is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, DNASE2B protein abundance shows 10,544 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, and LUAD as cancer lineages where DNASE2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNASE2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNASE2B survival associations across molecular data types. DNASE2B RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNASE2B RNA expression–survival associations across cancer types. High DNASE2B expression shows unfavorable associations in UVM and LGG, but favorable associations in KIRC, LUAD, KIRP and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DNASE2B RNA expression.
This table summarizes DNASE2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DNASE2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNASE2B shows lower tumor expression in LUAD, LUSC, COAD and READ and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher DNASE2B RNA expression in tumor versus normal tissue (log2 FC = +0.823, t-test p < 0.001).
This table shows molecular features associated with DNASE2B in patient tissues and cancer cell lines. In patient samples, DNASE2B shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, DNASE2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
